BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment
By Chris Wack
BeiGene shares were up 7% to $139.39 after the company said the European Commission has approved tislelizumab as a treatment for non-small cell lung cancer across multiple tumor types.
The approved indications for tislelizumab are, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of adult patients with squamous non-small cell lung cancer. It also can be used as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy.
BeiGene plans to combine the non-small cell lung cancer indications with the second-line indication under the brand name Tevimbra, which will launch in the first EU countries later in 2024. Tevimbra is approved in the U.S. and EU after prior chemotherapy.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 23, 2024 10:58 ET (14:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
Chewy Earnings: Market Likes Repurchase Program and Profit Improvements
-
This 5-Star Stock With a Dividend Yield That Tops 4% Is a Buy
-
After Earnings, Is Target Stock a Buy, Sell, or Fairly Valued?
-
Obesity Drug Stocks: Where to Invest Now
-
How to Invest Like Warren Buffett
-
DuPont Split Gives Investors Better Choices
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much